Jim Simons
VOR icon

Jim Simons’s Vor Biopharma VOR Stock Holding History

Jim Simons’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$608K Sell
33,011
-95,828
-74% -$1.45M ﹤0.01% 2533
2026
Q1 		$2.3M Buy
+128,839
New +$1.82M ﹤0.01% 1830
2025
Q4 		– Sell
-14,600
Closed -$711K – 3796
2025
Q3 		$711K Sell
14,600
-8,806
-38% -$354K ﹤0.01% 2650
2025
Q2 		$758K Sell
23,406
-11,666
-33% -$103K ﹤0.01% 2636
2025
Q1 		$503K Buy
35,072
+8,597
+32% +$206K ﹤0.01% 2740
2024
Q4 		$588K Sell
26,475
-11,326
-30% -$188K ﹤0.01% 2770
2024
Q3 		$529K Buy
37,801
+13,036
+53% +$238K ﹤0.01% 2767
2024
Q2 		$495K Buy
24,765
+8,032
+48% +$260K ﹤0.01% 2694
2024
Q1 		$793K Buy
16,733
+14,153
+549% +$621K ﹤0.01% 2631
2023
Q4 		$116K Buy
2,580
+755
+41% +$31.2K ﹤0.01% 3266
2023
Q3 		$77K Buy
1,825
+5
+0.3% +$271 ﹤0.01% 3300
2023
Q2 		$112K Buy
1,820
+400
+28% +$36.5K ﹤0.01% 3444
2023
Q1 		$153K Sell
1,420
-878
-38% -$97.3K ﹤0.01% 3366
2022
Q4 		$306K Buy
2,298
+703
+44% +$69.6K ﹤0.01% 3210
2022
Q3 		$127K Buy
1,595
+730
+84% +$71.8K ﹤0.01% 3517
2022
Q2 		$86K Buy
+865
New +$88.5K ﹤0.01% 3886

Other funds holding VOR

TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCPM III Services
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VR Adviser
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Jim Simons's VOR Position: Q2 2026 in Review

Jim Simons reduced its Vor Biopharma (VOR) stake by 74% in Q2 2026, selling an estimated $1.45M and leaving 33,011 shares worth $608K. The position accounts for ﹤0.01% of the portfolio, ranked #2533.

Jim Simons first reported a position in VOR in Q2 2022 and has held it in 16 quarters since. The position peaked at $2.3M in Q1 2026. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Jim Simons held 33,011 shares of Vor Biopharma worth $608K as of Q2 2026.
  • Jim Simons sold 95,828 Vor Biopharma shares in Q2 2026, an estimated $1.45M.
  • Vor Biopharma made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2533 holding.
  • Jim Simons first reported a position in Vor Biopharma in Q2 2022 and has held it in 16 quarters since.
  • Jim Simons's Vor Biopharma position peaked at $2.3M in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.